EUVIMEDEUVIMED felfedezése
Crossref

Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response

Alex Liu iD, Mounika Angirekula, Ahmed Elhawary, Kristin Mara, Tasha Kulai iD, Michael Leise, Kymberly D Watt

Clinical Transplantation · 2023

DOI: 10.1111/ctr.15050 ↗

At a glance

Journal article in Clinical Transplantation, 2023. Written by Alex Liu and 6 co-authors. Institution: Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Liver Transplantation, Hepatitis C, Chronic, Hepatitis C. Cited 5 times so far (Crossref); 16 references.

AbsztraktSubjectsBibliográfiai adatokCiteRelated studies

Abstract (original language)

Background

Liver transplant (LT) recipients with untreated hepatitis C (HCV) are at risk for cirrhosis graft failure. The advent of direct acting antiviral agents (DAA) has improved outcomes in HCV.

Aims

We aim to examine liver transplant outcomes and allograft fibrosis development/progression after sustained virologic response (SVR).

Methods

We performed a retrospective cohort study of 226 consecutive liver transplant recipients with HCV from 2007 to 2018. The cohort was split into transplants pre (Group A) and post (Group B) 2014 to reflect the introduction of DAAs. Fibrosis was monitored with liver biopsy and non‐invasive imaging.

Results

Group B had significantly improved HCV treatment rates and earlier SVR compared to Group A, with a cumulative incidence rate of SVR at 2 years of 86.7% versus 15.4% (HR = .11, p < .001). Prior to achieving SVR, Group A demonstrated worsening of fibrosis stage per year (+.21, p < .001) whereas Group B showed minimal change on protocol annual biopsy (−.02, p = .80). After SVR, most patients were followed non‐invasively and demonstrated stable or improved fibrosis stage over time. Patients undergoing transient elastography showed regression in fibrosis stage per year (−.19, p < .001).

Conclusion

HCV patients undergoing LT after 2014 had higher rates of SVR and improved clinically relevant transplant outcomes, namely less graft loss and death relating to HCV. Fibrosis progression halted or improved after SVR in both cohorts, suggesting that LT recipients with SVR do not require fibrosis monitoring even with established fibrosis prior to SVR.

Subjects

MeSH terms (MEDLINE)

Liver TransplantationHepatitis C, ChronicHepatitis CHumansAntiviral AgentsSustained Virologic ResponseRetrospective StudiesLiver CirrhosisHepacivirus

Author keywords

SVRcirrhosisfibrosis progressiongraft lossgraft survivalhepatitis Cliver transplantation

Substances

Antiviral Agents

Authors and institutions

  • Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Internal Medicine, St. Agnes Hospital, Baltimore, Maryland, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Digestive Care and Endoscopy, Dalhousie University, Halifax, Nova Scotia, Canada.

ORCID profiles: Alex Liu, Tasha Kulai

Cite

APA

Liu, A., Angirekula, M., Elhawary, A., Mara, K., Kulai, T., Leise, M., & Watt, K. D. (2023). Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response. Clinical Transplantation. https://doi.org/10.1111/ctr.15050

Vancouver

Liu A, Angirekula M, Elhawary A, Mara K, Kulai T, Leise M, et al. Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response. Clinical Transplantation. 2023. doi:10.1111/ctr.15050

BibTeX
@article{Liu2023,
  author = {Liu, Alex and Angirekula, Mounika and Elhawary, Ahmed and Mara, Kristin and Kulai, Tasha and Leise, Michael and Watt, Kymberly D},
  title = {Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.15050}
}
Start for free →